Effect of a Second GCV Administration on the Outcome of Late-Onset GVHD
| . | Mouse . | Clinical Status . | Second GCV Administration . | ||
|---|---|---|---|---|---|
| . | . | Onset . | Clinical Signs . | Days . | Outcome . |
| A | 6.21 | Day 40 | Weight loss, skin lesions, hunching* | − | Died at day 54 |
| 9.25 | Day 116 | Weight loss* | − | Died at day 145 | |
| B | 6.22 | Day 53 | Discrete skin lesions | Days 70 to 77 | Healthy at day 120 |
| 6.23 | Day 40 | Weight loss, skin lesions | Days 54 to 63 | Healthy at day 120 | |
| 9.11 | Day 80 | Weight loss, severe skin lesions, hunching | Days 133 to 140 | Partial recovery, death at day 179 | |
| . | Mouse . | Clinical Status . | Second GCV Administration . | ||
|---|---|---|---|---|---|
| . | . | Onset . | Clinical Signs . | Days . | Outcome . |
| A | 6.21 | Day 40 | Weight loss, skin lesions, hunching* | − | Died at day 54 |
| 9.25 | Day 116 | Weight loss* | − | Died at day 145 | |
| B | 6.22 | Day 53 | Discrete skin lesions | Days 70 to 77 | Healthy at day 120 |
| 6.23 | Day 40 | Weight loss, skin lesions | Days 54 to 63 | Healthy at day 120 | |
| 9.11 | Day 80 | Weight loss, severe skin lesions, hunching | Days 133 to 140 | Partial recovery, death at day 179 | |
This table summarizes the evolution of the 5 GCV-treated mice that presented a GVHD late after BM plus ΔTK T cells transplantation. The second GCV treatment was administered by intraperitoneal injection of 50 mg/kg twice daily, except for mouse 6.23 that was implanted with a miniosmotic pump delivering 50 mg/kg/d.
Abbreviation: −, no second GCV treatment.
GVHD confirmed histologically.